Prediction of prostate carcinoma stage by quantitative biopsy pathology

Cancer

Volumn 91, Issue 12, 2001, Pages 2322-2328

  Veltri, Robert W ^a   Miller, M Craig ^a   Partin, Alan W ^b   Poole, Edward C ^a   O'Dowd, Gerard J ^a  

^a UroCor Incorporated   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Algorithm; Logistic regression; Neural networks; Prostate carcinoma; Quantitative biopsy pathology; Staging

Indexed keywords

ADULT; AGED; ALGORITHM; ARTICLE; ARTIFICIAL NEURAL NETWORK; CANCER STAGING; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUANTITATIVE DIAGNOSIS;

BIOPSY; HUMANS; MALE; MODELS, THEORETICAL; NEOPLASM STAGING; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS;

EID: 0035876464     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010615)91:12<2322::AID-CNCR1264>3.0.CO;2-H     Document Type: Article

References (25)

1. Update on the appropriate staging evaluation for newly diagnosed prostate cancer
2. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men
3. Prostate specific antigen: A decade of discovery - What we have learned and where we are going
4. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate
5. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy
6. The optimal systematic biopsy scheme should include 8 rather than 6 biopsies: Results of a prospective clinical trial
7. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer
8. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy?
9. An algorithm for predicting non-organ confined prostate cancer using the results obtained from sextant core biopsies and prostate specific antigen level
10. The role of biopsy pathology, quantitative nuclear morphometry, and biomarkers in the pre-op prediction of prostate cancer staging and prognosis
11. Use of nuclear morphometry, Gleason histologic scoring, clinical stage, and age to predict disease%hyphen;free survival among patients with prostate cancer
12. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update
13. Predicting the pathology results of radical prostatectomy from preoperative information
14. Understanding artificial neural networks and exploring their potential applications for the practicing urologist
15. Predicting extracapsular extension of prostate cancer in men treated with radical prostatectomy: Results from the population based prostate cancer outcomes study
16. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy
17. Novel staging tool for localized prostate cancer: A pilot study using genetic adaptive neural networks
18. Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy
19. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer
20. Genetic algorithms: Principles of natural selection applied to computation
21. Free/total PSA ratios improve differentiation of benign and malignant disease of the prostate: Critical analysis of two different test populations
22. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer
23. Prostate cancer sampled on sextant needle biopsy: Significance of cancer on multiple cores from different areas of the prostate
24. Observations on pathology trends in 62,537 prostate biopsies obtained from urology private practices in the United States
25. Analysis of repeat biopsy results within one year following a non-cancer diagnosis